Immunotoxins consist of a monoclonal antibody (MoAb) or other targeting agent conjugated to a toxin which has the capability of causing cell death. Although many substances, including chemotherapeutic agents and radionuclides, are toxic to cells, the term 'immunotoxin' has generally been reserved for conjugates in which the toxic moiety is a ribosomal inhibiting protein. These substances act enzymatically to inhibit protein synthesis. Ribosomal inhibiting proteins occur naturally in a variety of bacteria, plants and animals. Many of them are lectins which bind to sugars and agglutinate cells [37, 106]. Examples of ribosomal inhibiting proteins are illustrated in Table 1.

Table 1

Ribosomal inhibiting preoteins


Maximum Tolerate Dose Graft Versus Host Disease Diphtheria Toxin Autologous Bone Marrow Transplantation Capillary Leak Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abu-Hadid MM, Bankert RB, Mayers GL. Antigenspecific drug-targeting used to manipulate an immune response in vivo. Proc Natl Acad Sci USA 1987; 84: 7232–7236.PubMedGoogle Scholar
  2. 2.
    Abuchowski A, Kazo GM, Verhoest Jr CR, Van Es T, et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparagninase conjugates. Cancer Biochem Biophys 1984; 7: 175–186.PubMedGoogle Scholar
  3. 3.
    Basham TY, Palladino MA, Badger CC, et al. Comparison of combinations of interferons with tumor specific and nonspecific monoclonal antibodies as therapy for murine B- and T-cell lymphomas. Cancer Res 1988; 48: 4196–4200.PubMedGoogle Scholar
  4. 4.
    Benjamin RJ, Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature 1986; 320:449–451.PubMedGoogle Scholar
  5. 5.
    Bernhard MT, Foon KA, Oeltmann TN, et al. Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain. Cancer Res 1983; 43:4420–4428.PubMedGoogle Scholar
  6. 6.
    Bhardwaj S, Spitler L, Mischak R, et al. Suppression of humoral immune response by oral cyclophosphamide in patients with metastatic melanoma treated with intravenous (IV) murine antimelanoma monoclonal antibody ricin-A chain immunotoxin-a Phase I/II study. Proc Am Soc Clin Oncol 1988; 7: 167.Google Scholar
  7. 7.
    Blakey DC, Thorpe PE. An overview of therapy with immunotoxins containing ricin or its A-chain. Ab Immunocon Radiopharm 1988; 1(1) 1–16.Google Scholar
  8. 8.
    Blakey DC, Watson GJ, Knowles PP, Thorpe PE. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res 1987; 47(4) 947–952.PubMedGoogle Scholar
  9. 9.
    Blakely DC, Wawrzynczak EJ, Wallace PM, Thorpe PE. Antibody toxin conjugates: a perspective. In: Progress in Allergy; Monoclonal Antibody Therapy, edited by H Waldmann, 45: 50–90, S. Karger AG, Basel, 1988.Google Scholar
  10. 10.
    Blattler WA. Blocked Ricin: A Potent Effector Molecule for Immunotoxin Therapy. In: Sixth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, 1991.Google Scholar
  11. 11.
    Blythman HE, Casellas P, Gros O, et al. Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumor cells. Nature 1981; 290: 145–146.PubMedGoogle Scholar
  12. 12.
    Bonavida B, Gifford GE, Kirchner H, and Old LJ, eds. Tumor Necrosis Factor/Cachectin and Related Cytokines, Basel, Switzerland, 1988.Google Scholar
  13. 13.
    Bookman MA, FitzGerald D, Frankel A, et al. Intraperitoneal immunotoxin therapy: two clinical studies. In: Antibody Immunoconjugates, and Radiopharm., edited by SE Order, 1990; 3(1): 70.Google Scholar
  14. 14.
    Bookman MA, Godfrey S, Padavic K, et al. Anti-transferrin receptor immunotoxin (IT) therapy: phase I intraperitoneal (i.p) trial. Proc ASCO 1990; 9: 187.Google Scholar
  15. 15.
    Borden EC. Augmented tumor-associated antigen expression by interferons. J Natl Cancer Inst 1988; 80(3) 148–149.PubMedGoogle Scholar
  16. 16.
    Braslawsky GR, Ligato P, Kaneko T, Greenfield R. Specific immunosuppression of mice by conjugating adriamycin (ADM) to a foreign serum protein. In: Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer, p. 162, San Diego, 1988.Google Scholar
  17. 17.
    Bridges SH, Fu-Sheng J, Johnson V, et al. Anti-CD4 modulates the host response to immunotoxin. In: Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, p. 154, San Diego, 1989.Google Scholar
  18. 18.
    Byers VS, Baldwin RW. Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunology 1988; 65(3) 329–335.PubMedGoogle Scholar
  19. 19.
    Byers VS, Clegg J, Durrant LG, et al. Abrogation of antibody responses in rats to murine monoclonal antibody 791T/36 by treatment with daunomycin cis-aconityl 791T/36 conjugates. In: Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, p. 68, San Diego, 1989.Google Scholar
  20. 20.
    Byers VS, Henslee P, Kernan N, et al. Therapeutic response to a pan T lymphocyte monoclonal antibodyricin A chain immunotoxin in steroid refractory graft versus host disease (GVHD). Blood 1987; 70: 3041.Google Scholar
  21. 21.
    Byers VS, Pawlucyzk I, Berry N, et al. Potentiation of anti-carcinoembryonic antigen immunotoxin cytotoxicity by monoclonal antibodies reacting with co-expressed carcinoembryonic antigen epitopes. J Immunol 1988; 140: 4050–4055.PubMedGoogle Scholar
  22. 22.
    Byers VS, Pimm MV, Perkins AC, et al. Biodistribution and biokinetics of intraperitoneally injected immunotoxin 791-RTA and its antibody in recurrent ovarian cancer. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, p. 46, San Diego, 1989.Google Scholar
  23. 23.
    Byers VS, Rodvien R, Grant K, et al. Phase I study of monoclonal antibody-ricin A chain immunotoxin Xoma- Zyme [registered trademark]-791 in patients with metastatic colon cancer. Cancer Res 1989; 49: 6153–6160.PubMedGoogle Scholar
  24. 24.
    Byers VS. Therapy of hemotologic manlignancies with anti T-lymphocyte ricin A chain immunotoxins. In: Fifth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, p. 13, San Diego, 1990.Google Scholar
  25. 25.
    Casellas P, Bourrie BJP, Gros P, Jansen FK. Kinetics of cytotoxicity induced by immunotoxins: enhancement by lysosomotropic amines and carboxylic ionophores. J Biol Chem 1984; 259(15) 9359–9364.PubMedGoogle Scholar
  26. 26.
    Davis FF, VanEs T, Palczuk NC. Non-immunogenic polypeptides. US Patent No 4,296,097,1979.Google Scholar
  27. 27.
    Dell’Arciprete L, Colombatt M, Stevanoni G. Potentiation of RTA conjugates by HSA -monensin. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, p. 155, San Diego, 1989.Google Scholar
  28. 28.
    Diener E, Diner UE, Sinha A, et al. Specific immunosuppression by immunotoxins containing daunomycin. Science 1986; 231: 148–150.PubMedGoogle Scholar
  29. 29.
    Dresser DW. Tolerance induction as a model for cell differentiation. Br Med Bull 1976; 32(2) 147–151.PubMedGoogle Scholar
  30. 30.
    Eiklid K, Olsnes S, Pihl A. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of Hela cells. Expl Cell Res 1980; 126: 321–326.Google Scholar
  31. 31.
    Engert A, Gottstein C, Winkler U, et al. Experimental treatment of human Hodgkin’s disease with ricin A-chain immunotoxins. Leukemia & Lymphoma 1994; 13(5-6): 441–448.Google Scholar
  32. 32.
    Epstein C, Lynch T, Shefner J, et al. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int J of Cancer-Supp 1994; 8: 57–59.Google Scholar
  33. 33.
    Esber HJ, Goad MEP, Zavorskas PA, et al. Preclinical evaluation of an immunoconjugate, blocked ricin and anti-human B-lymphocyte monoclonal antibody, in cynomolgus monkeys. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, p. 150, San Diego, 1989.Google Scholar
  34. 34.
    Falini B, Bolognesi A, Flenghi L, et al. Response of refractory Hodgkin’s disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339(8803) 1195–1196.PubMedGoogle Scholar
  35. 35.
    Foon KA, Bernhard M, Oldham RK. Monoclonal antibody therapy: assessment by animal tumor models. J Biol Response Modif 1982; 1: 277–304.Google Scholar
  36. 36.
    Foon KA. Biological response modifiers: the new immunotherapy. Cancer Res 1989; 49(7) 1621–1639.PubMedGoogle Scholar
  37. 37.
    Franz H and Ziska P. Affinitins: combining sites containing proteins. In: Lectins: Biology, Biochemistry, Clinical Biochemistry, edited by TC Bog-Hansen, Volume 1. Walter de Gruyter, New York, 1981.Google Scholar
  38. 38.
    Ghetie MA, May RD, Till M, et al. Evaluation of ricin A chain-containing immunotoxins directed against CD 19 and CD22 antigens on normal and malignant human Bcells as potential reagents for in vivo therapy. Cancer Res 1988; 48(9) 2610–2617.PubMedGoogle Scholar
  39. 39.
    Gilliland DG, Steplewski Z, Collier RJ, et al. Antibody directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci USA 1980; 77: 4539–4543.PubMedGoogle Scholar
  40. 40.
    Goldberg MR, Heimbrook DC, Russo P, et al. Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res 1995; 1: 57–61.PubMedGoogle Scholar
  41. 41.
    Gonzalez R, Salem P, Bunn PA, et al. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial. Mol Biother 1991; 3: 192–196.PubMedGoogle Scholar
  42. 42.
    Gould BJ, Borowitz MJ, Groves ES, et al. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst 1989; 81(10) 775–781.PubMedGoogle Scholar
  43. 43.
    Greiner JW, Fisher PB, Pestka S, Schlom J. Differential effects of recombinant human leukocyte interferons on cell surface antigen expression. Cancer Res 1986; 46: 4984–4990.PubMedGoogle Scholar
  44. 44.
    Griffin TW, Pagnini PG, McGrath JJ, et al. In vitro cytotoxicity of recombinant ricin A chain-antitransferrin receptor immunotoxin against human adenocarcinomas of the colon and pancreas. J Biol Resp Modif 1988; 7(6) 559–567.Google Scholar
  45. 45.
    Grossbard ML, Freedman AS, Ritz J, et al. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 1992; 79(3) 576–585.PubMedGoogle Scholar
  46. 46.
    Grossbard ML, Gribben JG, Freedman AS, et al. Immunotherapy with anti-B4-blocked ricin (anti-B4-bR) for Bcell NHL: immunotoxin therapy of minimal residual disease (MRD). Antibody Immunoconj and Radiopharm 1992; 5(1) 152.Google Scholar
  47. 47.
    Grossbard ML, Gribben JG, Freedman AS, et al. Adjuvant immunotoxin therapy with anti-b4-blocked ricin after autologous bone marrow transplantation for patients with b-cell non-Hodgkin’s lymploma. Blood 1993; 81(9) 2263–2271.PubMedGoogle Scholar
  48. 48.
    Grossbard ML, Lambert JM, Goldmacher VS, et al. Anti- B4-blocked ricin: A Phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993; 11:726–737.PubMedGoogle Scholar
  49. 49.
    Grossbard ML, O’Day S, Gribben JG, et al. A phase II study of anti-B4-blocked ricin (anti-B4-bR) therapy following autologous bone morrow transplantation (ABMT) for B-cell non-Hodgkin’s lymphoma (B-NHL). Proc ASCO 1994; 13:293.Google Scholar
  50. 50.
    Hanna Jr MG, Key ME, Oldham RK. Biology of cancer therapy: some new insights into adjuvant treatment of metastatic solid tumors. J Biol Response Modif 1983; 4: 295–309.Google Scholar
  51. Henslee PJ, Byers VS, Jennings CD, et al. A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 [registered trademark] following histoincompatible partialy T-depleted marrow grafts. Transplant Proc 1989; 21(1 Part 3): 3004–3007.PubMedGoogle Scholar
  52. 52.
    Henslee PJ, Byers VS, Jennings CD, et al. Reduction of graft versus host disease in Recipients of histoincompatible marrow transplant following administration of XomaZyme [registered trademark]-H65. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, p. 43, San Diego, 1989.Google Scholar
  53. 53.
    Hertler A A, Frankel AE. Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin One 1989; in press.Google Scholar
  54. 54.
    Hertler A A, Schlossman DM, Borowitz MJ, et al. An anti- CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albuminmonensin .Int J Cancer 1989; 43: 215–219.PubMedGoogle Scholar
  55. 55.
    Hertler AA, Schlossman DM, Borowitz MJ, et al. A phase I study of TlOl-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia, J Biol Resp Modif 1987; 7: 97–113.Google Scholar
  56. 56.
    Hwang KM, Foon KA, Cheung PH, et al. Selective antitumor effect of a potent immunoconjugate composed of the A chain of abrin and monoclonal antibody to a hepatoma associated antigen. Cancer Res 1984; 44:4578–4586.PubMedGoogle Scholar
  57. 57.
    Jain RK, Ward-Hartley K. Tumor blood flow - characterization, modifications, and role in hyperthermia. IEEE Trans Sonics and Ultrasonics 1984; SU-31(5) 504–526.Google Scholar
  58. 58.
    Jansen FK, Blythman HE, Carriere D, et al. Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev 1982; 62: 185–215.PubMedGoogle Scholar
  59. 59.
    Jirtle R. Chemical modification of tumour blood flow. Int J Hyperthermia 1988; 4(4) 355–371.PubMedGoogle Scholar
  60. 60.
    Kernan NA, Byers V, Scannon PJ, et al. Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin. JAMA 1988; 259(21) 3154–3157.PubMedGoogle Scholar
  61. 61.
    Key ME, Bernhard MI, Hoyer LC, et al. Guinea pig 10 hepatocarcinoma model for monoclonal antibody sertherapy: in vivo localization of a monoclonal antibody in normal and malignant tissues. J Immunol 1983; 139: 1451–1457.Google Scholar
  62. 62.
    Kishida K, Masuho Y, Saito M, et al. Ricin A chain conjugated with monoclonal anti-L1210 antibody. In vitro and in vivo antitumor activity. Cancer Immun Immunother 1983; 16:93.Google Scholar
  63. 63.
    Khazaeli M, LoBuglio AF, Wheeler R, et al. The effects of immunosuppressive regimens on human immune response to murine monoclonal anti-melanoma antibodyricin A chain. Proc Am Assoc Cancer Res 1988; 29: 418.Google Scholar
  64. 64.
    Koehler M, Hurwitz CA, Krance RA, et al. XomaZyme- CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graftversus- host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplantation 1994; 13(5) 571–575.PubMedGoogle Scholar
  65. 65.
    Krance R, Heslop HE, Mahmoud H, et al. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. Bone Marrow Transplantation 1993; 11(1) 33–66.PubMedGoogle Scholar
  66. 66.
    Krolick KA, Uhr JW, Slavin S, and Vitetta ES. In vivo therapy of a murine B cell tumor (BCL1) using antibodyricin A chain immunotoxins. J Exp Med 1982; 155: 1797–1809.PubMedGoogle Scholar
  67. 67.
    Krolick KA, Villemez C, Isakson P, et al. Selected killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc Natl Acad Sci USA 1980; 77: 5419.PubMedGoogle Scholar
  68. 68.
    Krolick KA, Yuan D, Vitetta ES. Specific killing of a human breast carcinoma cell line by a monoclonal antibody coupled to the A-chain of ricin Cancer, Immunol Immunother 1981; 12: 39–41.Google Scholar
  69. 69.
    Laurent G, Pris J, Farcet J P, et al. Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood 1986; 67: 1680–1687.PubMedGoogle Scholar
  70. 70.
    Lee WY, Sehon A. Suppression of reaginic antibodies to drugs employing polyvinyl alcohol as carrier therefor. US Patent No 4,296,097,1981.Google Scholar
  71. 71.
    Lee WY, Sehon AH. Suppression of reaginic antibodies. Immunol Rev 1978; 41: 200.PubMedGoogle Scholar
  72. 72.
    Leichner P, Yang N, Wessels B. Dosimetry and treatment planning in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1989; in press.Google Scholar
  73. 73.
    LeMaistre CR, Meneghetti C, Rosenblum M, et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486 IL- 2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992; 79: 2547–2554.Google Scholar
  74. 74.
    LeMaistre CF, Meneghetti C, Yau JC, et al. Pre-emptive therapy of graft vs. host disease (GVHD) with a pan-T-cell immunotoxin (IT) is associated with accelerated engraftment. In: Antibody Immunoconjugates, and Radiopharm, edited by SE Order, 1990; 3(1): 70.Google Scholar
  75. 75.
    LeMaistre CF, Craig FE, Meneghetti C, et al. Phase I trial of a 90-minute infusion of the fusion toxin DAB486 IL-2 in hematological cancers. Cancer Research 1993; 53: 3930–3934.PubMedGoogle Scholar
  76. 76.
    LeMaistre CF; Rosen S, Frankel A, et al. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous Tcell lymphoma.(61) Blood 1991; 78(5) 1173–82.PubMedGoogle Scholar
  77. 77.
    Letvin NL, Goldmacher VS, Ritz J, et al. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: in vivo stability of disulfide- linked immunotoxin conjugates. J Clin Invest 1985; 77: 977–984.Google Scholar
  78. 78.
    LoBuglio AF, Khazaeli MB, Lee J, et al. Pharmacokinetics and immune response to Xomazyme-Mel in melanoma patients. Ab Immunocon Radiopharm 1988; 1: 305–310.Google Scholar
  79. 79.
    Lynch TJ Jr. Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer. Chest 1993; 103(4 Suppl) 436S–439S.PubMedGoogle Scholar
  80. 80.
    Lynch TJ, Coral J, Shefner AD, et al. Phase I trial of the novel immunotoxin N901-blocked ricin (N901-BR): demonstration of clinical activity in small cell lung cancer. Proc of ASCO 1993; 12,293.Google Scholar
  81. 81.
    Matsui M, Nakanishi T, Noguchi T, and Ferrone S. Synergistic in vitro and in vivo anti-tumor effect of daunomycin-anti-96-kDa melanoma-associated antigen monoclonal antibody CL 207 conjugate and recombinant IFN-gamma J Immunol 1988; 141: 1410–1417.PubMedGoogle Scholar
  82. 82.
    Matsui M, Temponi M, Ferrone S. Characterization of a monoclonal antibody-defined human melanomaassociated antigen susceptible to induction by immune interferon. J Immunol 1987; 139: 2088.PubMedGoogle Scholar
  83. 83.
    Morgan AC Jr, Manger R, Pearson JW, et al. Immunoconjugates of Pseudomonas exotoxin A: evaluation in mice, monkeys, and man. Cancer Detection and Prevention 1991; 15(2): 137–43.PubMedGoogle Scholar
  84. 84.
    Morgan AC, Siram G, Weiden P, et al. (1989): Pseudomonas exotoxin A immunoconjugates: preclinical and clinical evaluation in mice, monkeys, and man. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, pp. 44-45, San Diego, 1989.Google Scholar
  85. 85.
    Msirikale J, Klein J, Schroeder J, Order S. Int J Radiat Oncol Biol Phys 1987; 13: 1839–1844.PubMedGoogle Scholar
  86. 86.
    Murphy J. Proceedings of the Society of Biological Therapy, Pittsburgh, 1991.Google Scholar
  87. 87.
    Murray PW, McLaughlin MG, Rosenblum H, et al. Phase I trial of anti-B4 blocked ricin (B4bR) given as a 28 day continuous infusion (CI). Proceedings of the Society for Biological Therapy 1994; 48.Google Scholar
  88. 88.
    Nadler L. Anti-B4 blocked ricin immunotoxin therapy for B cell leukemias and lymphomas. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, p. 49, San Diego, 1989.Google Scholar
  89. 89.
    Nadler L. Immunotoxin therapy for B cell malignancies. In: Fifth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, p. 13, San Diego, 1990.Google Scholar
  90. 90.
    Nilsson IM, Freiburghaus C, Sundqvist S, Sandberg H. Removal of specific antibodies from whole blood in a continuous extracorporeal system. Plasma Ther Transfus Technol 1984; 5: 127–134.Google Scholar
  91. 91.
    Oldham RK, Lewis M, Orr DW, et al. Adriamycin customtailored immunoconjugates in the treatment of human malignancies. Mol Biother 1988; 1(2) 103–113.PubMedGoogle Scholar
  92. 92.
    Oldham RK. Biological Response Modifiers Program: Subcommittee report. J Natl Cancer Inst, Monograph 1983;63:235–247.Google Scholar
  93. 93.
    Oratz R, Speyer JL, Wernz JC, et al. Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial. Journal of Biological Response Modifiers 1990; 9(4) 345–54.PubMedGoogle Scholar
  94. 94.
    Orr D, Oldham R, Lewis M, et al. Phase I trial of mitomycin C immunoconjugates cocktails in human malignancies. Mol Biother 1989; 1(4) 229–240.PubMedGoogle Scholar
  95. 95.
    Pai LH, Bookman MA, Ozols RF, et al. Clinical evaluation of intraperitoneal Pseudomonal exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 1991; 9(12) 2088–2090.Google Scholar
  96. 96.
    Pastan I, FitzGerald D. Novel cytotoxic agents created by the fusion of growth factor and toxin genes. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, pp. 36-37, San Diego, 1989.Google Scholar
  97. 97.
    Pietersz GA, Smyth MJ, Kanellos J, et al. Preclinical and clinical studies with a variety of immunoconjugates. Ab Immunocon Radiopharm 1988; 1(1) 79–103.Google Scholar
  98. 98.
    Pimm MV Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations. Crit Rev Ther Drug Carrier Syst 1988; 5(3): 189–227.PubMedGoogle Scholar
  99. 99.
    Pirker R. Immunotoxins against solid tumors. J Cancer Res Clin Oncol 1988; 114(4) 385–93.PubMedGoogle Scholar
  100. 100.
    Pirker R, FitzGerald DJP, Raschack M, et al. Enhancement of the activity of immunotoxins by analogues of verapamil. Cancer Res 1989; 49:4791–4795.PubMedGoogle Scholar
  101. 101.
    Press OW, Vitetta ES, Farr AG, et al. Evaluation of ricin A chain immunotoxins directed against human T cells. Cellular Immunol 1986; 102: 10–20.Google Scholar
  102. 102.
    Ramakrishnan S, Houston LL. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors: pokeweed antiviral protein or ricin A chain. Cancer Res 1984; 44: 1398.PubMedGoogle Scholar
  103. 103.
    Raso V, Ritz J, Basola M, Schlossman SF. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. Cancer Res 1982; 42: 457.PubMedGoogle Scholar
  104. 104.
    Robinson WA, Adlakha A, Lamb MR, et al. Therapy of metastatic melanoma using single dose murine monoclonal antimelanoma antibody conjugated with ricin A chain (SMMME-001 -RTA). Second International Congress of Melanoma, Venice, Italy, 1989.Google Scholar
  105. 105.
    Rodwell JD, Alvarez VL, Lee C, et al. Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc Natl Acad Sci USA 1986; 83: 2632–2636.PubMedGoogle Scholar
  106. 106.
    Rudiger H. Lectins, an introduction. In: Lectins: Biology, Biochemistry, Clinical Biochemistry, edited by TC Bog- Hansen, Volume 1. Walter de Gruyter, New York, 1981.Google Scholar
  107. 107.
    Santos GW. Immunosuppressive drugs I. Federation Proceedings 1967; 26: 907–913.PubMedGoogle Scholar
  108. 108.
    Sausville E, Headlee D, Stetler-Stevenson M, et al. A phase I trial in B-cell lymphoma using anti-CD22 immunotoxin (IT) IgG-RFB4-SMPT-dgA: activity and determinants of toxicity. Proc ASCO 1994; 13: 384.Google Scholar
  109. 109.
    Scannon PJ. (1989): Suppression of the human immune response to immunotoxins with drugs. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, p. 63, San Diego, 1989.Google Scholar
  110. 110.
    Sehon AH, Lang GM. The use of nonionic, water soluble polymers for the synthesis of tolerogenic conjugates of antigens. In: Mediators of Immune Regulation and Immunotherapy, edited by SK Singhal and TL Delovitch, pp. 190-203, Elsevier Science Publishing Co., Inc., 1986.Google Scholar
  111. 111.
    Selvaggi K, Saria EA, Schwartz R, et al. Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporin A in patients with metastatic melanoma. Journal of Immunotherapy 1993; 13:201–207.PubMedGoogle Scholar
  112. 112.
    Seon BK. Specific killing of human T leukemia cell by immunotoxins prepared with ricin A chain and monoclonal antihuman T-cell leukemia antibodies. Cancer Res 1984; 44:259.PubMedGoogle Scholar
  113. 113.
    Seon BK, Yokota S, Hara H, Luo Y. Synergistic effects of anti-human leukemia immunotoxins and recombinant a- Interferon in the in vivo suppression of tumor growth. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, p. 41, San Diego, 1989.Google Scholar
  114. 114.
    Seto M, Umemoto M, Saito M, et al. Monoclonal anti- MN46 antibody: ricin A chain conjugate; in vivo and in vitro antitumor activity. Cancer Res 1982; 42: 5209.PubMedGoogle Scholar
  115. 115.
    Sivan G, Pearson JW, Bohn W, et al. Immunotoxins to human melanoma associated antigen: comparison of gelonin with ricin and other A-chain conjugates. Cancer Res 1987; 47: 3169–3173.Google Scholar
  116. 116.
    Smith RT. Immunological tolerance of nonliving antigens. In: Advances in Immunology, edited by WH Taliaferro and JH Humphrey, pp. 67–129. Academic Press, New York, 1961.Google Scholar
  117. 117.
    Smyth M J, Pietersz G A, McKenzie IFC. Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates. JNCI 1987; 79(6) 1367–1373.PubMedGoogle Scholar
  118. 118.
    Smyth MJ, Pietersz GA, McKenzie IFC. Increased antitumor effedt of immunoconjugates and tumor necrosis factor. Cancer Res 1988; 48: 3607–3612.PubMedGoogle Scholar
  119. 119.
    Spitler LE. Clinical Studies: Solid Tumors. In: Immunotoxins, edited by Arthur E. Frankel, pp. 491–512. Martinus Nijhoff, Boston, 1988.Google Scholar
  120. 120.
    Spitler LE. Immunotoxins. In Principles of Cancer Biotherapy. Edited by Robert K. Oldham, pp.433–456. Marcel Dekker, Inc., New York, 1991.Google Scholar
  121. 121.
    Spitler LE, Mischak R, Scannon P. Therapy of metastatic malignant melanoma using Xomazyme-Mel, a murine monoclonal antimelanoma ricin A chain immunotoxin. Nuclear Medicine and Biology International Journal of Applied Radiation and Isotopes, Part B 1989; 16(6) 625–627.Google Scholar
  122. 122.
    Spitler LE, Rio M, delKhentigan A, et al. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A-chain immunotoxin. Cancer Res 1987; 47: 1717–1723.PubMedGoogle Scholar
  123. 123.
    Spitler LE, von Wussow P, Carey RW, et al. Phase II trial of a monoclonal antimelanoma antibody ricin A chain immunotoxin in therapy of malignant melanoma. Second International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, San Diego, 1987.Google Scholar
  124. 124.
    Thorpe PE, Brown ANF, Bremner JAG, et al. An immunotoxin composed of monoclonal anti-Thy-1.1 antibody and a ribosome inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. J Natl Cancer Inst 1985; 75: 151–159.PubMedGoogle Scholar
  125. 125.
    Thorpe PE, Wallace PM, Knowles PP, et al. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A chain and hindered disulfide linkages. Cancer Res 1988; 48: 6396–6403.PubMedGoogle Scholar
  126. 126.
    Trowbridge IS, Domingo DL. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells. Nature (Lond) 1981; 294: 171.Google Scholar
  127. 127.
    Vitetta ES. In: Proceedings of the Society of Biological Therapy, Pittsburgh, 1991.Google Scholar
  128. 128.
    Vitetta ES, Stone M, Amlot P, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Research 1991; 51(15) 4052–8.PubMedGoogle Scholar
  129. 129.
    Vitetta E, Thorpe P. Immunotoxins to treat B cell lymphomas. In: Fifth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I Royston and RD Dillman, p. 13, San Diego, 1990.Google Scholar
  130. 130.
    Volkman DJ, Ahmad A, Fauci AS, Neville Jr DM. Selective abrogation of antigen-specific human B cell responses by antigen-ricin conjugates. J Exp Med 1982; 156:634–639.PubMedGoogle Scholar
  131. 131.
    Weiner LM, O’Dwyer J, Kitson J, et al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9- recombinant ricin A chain immunoconjugate. Cancer Res 1989; 49(14) 4062–4067.PubMedGoogle Scholar
  132. 132.
    Weisdorf D, Filipovich A, McGlave P, et al. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation. Bone Marrow Transplantation 1993; 12(5) 531–536.PubMedGoogle Scholar
  133. 133.
    Yamaizumi M, Mekada E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978; 15: 245–250.PubMedGoogle Scholar
  134. 134.
    Youle RJ, Neville DM Jr. Kinetics of protein synthesis inactivation by ricin A anti-thy 1.1 monoclonal antibody hybrids. J Biol Chem 1982; 257: 1598.PubMedGoogle Scholar
  135. 135.
    Yu Y H, Ramakrishnan S, Houston L, et al. Synergistic antitumor activity of immunotoxins reactive with human breast carcinomas. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I. Royston and R.D. Dillman, p. 40, San Diego, 1989.Google Scholar
  136. 136.
    Zalebert JR, Pielersz G, Toohey B, et al. (1989): Phase I-II study of A ricin monoclonal antibody conjugate in colon cancer. Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, edited by I. Royston and R.D. Dillman, p. 47, San Diego, 1989.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Lynn E. Spitler
    • 1
  1. 1.Jenner Biotherapies, IncSan RamonUSA

Personalised recommendations